Ibrahim Ahmed S, Abdelhai Ahmed M, Mahmoud Awatif, Alghazali Mohamed, Hamza Eltayeb, Hajalhasan Mohamed, Mohammed Mohammed, Abbas Ahmed
Trauma and Orthopedics, Nile University, Khartoum, SDN.
Trauma and Orthopedics, Royal Care International Hospital, Khartoum, SDN.
Cureus. 2025 Jul 2;17(7):e87151. doi: 10.7759/cureus.87151. eCollection 2025 Jul.
Surgical site infections (SSIs) remain a significant challenge in orthopedic surgery, despite existing methods for lowering SSI rates, contributing to increased morbidity, mortality, and healthcare costs. The search for more effective prophylaxis strategies is a major area of research to reduce postoperative morbidity and mortality. Topical application of vancomycin powder (VP) has been suggested as an adjunctive measure for reducing SSIs.
To evaluate the effectiveness of intraoperative topical VP in preventing SSIs in orthopedic surgeries.
A comparative hospital-based observational study was conducted at Future Hospital, Khartoum, from September 2021 to October 2022. A total of 300 patients undergoing orthopedic surgery were enrolled and divided into two equal groups: a VP group (n=150) receiving intra-wound VP and a control group (n=150) without VP. Data on postoperative SSI and other variables were collected from hospital records and analyzed using IBM SPSS Statistics for Windows, Version 26 (Released 2018; IBM Corp., Armonk, New York, United States).
A total of 300 patients were included. The mean patient age was 42.4±19.5 years, and 205 patients (68.3%) were male. There were no significant differences between observed cases and control groups in age, gender, occupation, diagnosis, and type of operations. Fractures were the most common indication for surgery (158 patients, 52.7%), and decompression with fixation was the most frequent procedure (143 patients, 47.7%). Patient age was significantly associated with SSIs (p=0.009), with older patients showing higher rates. The SSI rate was significantly lower in the topical VP group (four patients, 2.7%) compared to the control group (11 patients, 7.3%) (P=0.042). No vancomycin-related adverse reactions were observed.
The intraoperative application of VP significantly reduced the incidence of SSIs in orthopedic surgeries. Routine use of VP should be considered, especially in high-risk patients.
尽管现有降低手术部位感染(SSI)发生率的方法,但骨科手术中的SSI仍然是一个重大挑战,这会导致发病率、死亡率增加以及医疗成本上升。寻找更有效的预防策略是降低术后发病率和死亡率的一个主要研究领域。有人建议局部应用万古霉素粉末(VP)作为降低SSI的辅助措施。
评估术中局部应用VP预防骨科手术中SSI的有效性。
2021年9月至2022年10月在喀土穆未来医院进行了一项基于医院的对比观察性研究。共有300例接受骨科手术的患者入组并分为两组:VP组(n = 150)接受伤口内VP,对照组(n = 150)不使用VP。从医院记录中收集术后SSI及其他变量的数据,并使用IBM SPSS Statistics for Windows 26版(2018年发布;IBM公司,美国纽约州阿蒙克)进行分析。
共纳入300例患者。患者平均年龄为42.4±19.5岁,205例患者(68.3%)为男性。观察组与对照组在年龄、性别、职业、诊断和手术类型方面无显著差异。骨折是最常见的手术指征(158例患者,52.7%),减压固定是最常见的手术方式(143例患者,47.7%)。患者年龄与SSI显著相关(p = 0.009),年龄较大的患者发生率较高。局部应用VP组的SSI发生率(4例患者,2.7%)显著低于对照组(11例患者,7.3%)(P = 0.042)。未观察到与万古霉素相关的不良反应。
术中应用VP可显著降低骨科手术中SSI的发生率。应考虑常规使用VP,尤其是在高危患者中。